Phase 2 N=133 Behavioral Economic Analysis of Demand for Marijuana
Marijuana Smoking
Primary: Validity of the Marijuana Purchase Task (MPT) — 63 percentage of participants — p=.00000004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=36 Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks
Marijuana Use Disorder
Primary: Change From Baseline in Iowa Gambling Task Scores [Objective Measure of Decision Making] — 3.7; 10.1; 4.4 mean number of cards
Phase 2 N=35 Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper
Marijuana Dependence
Primary: Plasma THC — 6; 53; 70; 7 ng/mL
Phase 2 N=23 Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana
Marijuana Smoking
Primary: Subjective Marijuana Effects — 13; 15; 16; 16 units on a scale (0-100mm)
Phase 1 N=10 Marijuana Effects on Simulated Driving Performance
Cannabis · Cannabis Use · Marijuana
Primary: Mean Peak for Standard Deviation in Lane Position (SDLP) — 1.33; 1.37; 1.42; 1.35 centimeters
Phase 2 N=24 The Effect of Prescription Medications in Marijuana Users
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
N/A N=67 Clinical Trial Tobacco Marijuana
Cannabis Use Disorder · Tobacco Use Disorder
Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33
Phase 2 N=157 Marijuana's Impact on Alcohol Motivation and Consumption
Alcohol Drinking · Marijuana
Primary: Alcohol Craving — 2.54; 2.64; 2.65; 2.55 units on a scale
Phase 2 N=14 Effects of Marijuana on Symptoms of OCD
Obsessive-Compulsive Disorder
Primary: Yale-Brown Obsessive-Compulsive Challenge Scale (YBOC-CS) — 17.45; 17.00; 17.09; 13.36 score on a scale — p=.577
Phase 2 N=34 Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers
Pain Threshold · Mood
Primary: Pain Tolerance — 6.1; 2.8; 4.9; 1.5 seconds
N/A N=107 Project CheckUP: A Brief Behavioral Intervention for Quitline Callers Who Use Marijuana (MJ) and Tobacco
Smoking Cessation · Marijuana Use
Primary: Number of Calls Completed — 123; 141 Total number of calls
N/A N=51 Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study
Chronic Pain
Primary: Alcohol Demand: Breakpoint — -6.00; -2.07; -1.81; -1.09 dollars/drink — p=.26
Early Phase 1 N=10 Influence of Edible Marijuana on Endurance Exercise Performance
Endurance Exercise
Primary: Comparison of Blood Lactate Levels During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo. — 0.9699; 1.1437; 1.26345; 1.3618…
N/A N=184 Brain Nicotine Receptor Density in Veteran Smokers
Positron Emission Tomography
Primary: PET Scan, Rating Scales — 7.1; 8.6; 7.9; 8.0 Vt/fp or mL/cm3
Phase 4 N=127 Nicotine Patch for Marijuana Withdrawal
Marijuana Dependence
Primary: Profile of Mood Scale Total Negative Affect (Tension + Depression + Anger) — 8.52; 8.096; 5.14; 4.615 units on a scale
Phase 2 N=174 UH3 Varenicline for Cannabis Use Disorder
Cannabis Use Disorder
Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions
Phase 2 N=49 Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana
Marijuana Use
Primary: Change in Mean Subjective Mood Scores as a Function of Marijuana Strength and Naltrexone Dose. — 8.0; 25.0; 6.7; 34.0 units on a scale
Phase 2 N=50 Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
Smoking, Marijuana
Primary: Mood Scale - Subscale 'Feeling High' — 4.35; 2.48; 0.39; 6.55 units on a scale VAS 1-100 mm
Phase 1 N=8 Reinforcing Effects of Marijuana and Opioids
Marijuana Use · Opioid Use
Primary: Self-Administration of Drug Units Earned — 0.00; 3.83; 3.67; 0.00 Number of drug units
Phase 2 N=72 Varenicline Treatment for Cannabis Use Disorder
Substance Use Disorder
Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale
N/A N=153 Treatment for Adolescent Marijuana Abuse
Marijuana Abuse
Primary: Marijuana Abstinence (2 Weeks or Greater) — 72.5; 68.6; 45.1 percentage of participants
Phase 3 N=8 Vaping THC From Electronic Cigarettes
Marijuana Dependence
Primary: Mean Delivered and Retained Doses — 0.016; 0.018; 0.026 grams (g)
Phase 2 N=199 The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking
Cannabis Intoxication
Primary: Change in Composite Drive Score (CDS) From Pre-smoking Simulation — -.09; .12; .01; -.17 z-score — p=<0.001
N/A N=253 Pain Research: Innovative Strategies With Marijuana
Chronic Pain · Chronic Low Back Pain · Cannabis Use
Primary: Pain Interference: Roland Morris Disability Questionnaire (RMDQ) — 8.028; 9.635; 9.034; 6.194 score on a scale
Phase 4 N=181 Cannabis and Tobacco Co-use Study
Tobacco Use Disorder
Primary: Number of Participants With Biologically Verified 7-day Point Prevalence Tobacco Abstinence at the End of Treatment (Week 12) — 30; 40; 36; 42 Participants
N/A N=269 Effect of Medical Marijuana on Neurocognition and Escalation of Use
Pain · Insomnia · Depression
Primary: Mean Difference in Number of Cannabis Use Disorder Symptoms Averaged Over 2, 4, and 12 Weeks — 0.39; 0.12 score on a scale — p=<0.001
Phase 2 N=16 Baclofen Effects on Marijuana Dependence
Marijuana Dependence
Primary: Urine Drug Screen — 0; 0 Participants
Phase 3 N=42 Vaporized Cannabis and Spinal Cord Injury Pain
Spinal Cord Injuries · Spinal Cord Diseases
Primary: Number of Participants Achieving a Reduction in Pain Intensity of 30% or More — 18; 26; 35 participants — p=<.05
N/A N=60 Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
Marijuana Use · Pregnancy
Primary: Number of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery — 6; 7; 6; 3 Participants
Early Phase 1 N=43 Brain Imaging of Cannabinoid Receptors
Cannabis Use Disorder · Cannabis Dependence, Continuous
Primary: Distribution Volume (VT) — 1.27; 1.54; 1.14; 1.31 mL/cm^3 — p=0.02